DE69607034T2 - Pcna bindende substanz - Google Patents

Pcna bindende substanz

Info

Publication number
DE69607034T2
DE69607034T2 DE69607034T DE69607034T DE69607034T2 DE 69607034 T2 DE69607034 T2 DE 69607034T2 DE 69607034 T DE69607034 T DE 69607034T DE 69607034 T DE69607034 T DE 69607034T DE 69607034 T2 DE69607034 T2 DE 69607034T2
Authority
DE
Germany
Prior art keywords
fen1
pcna
fragments
binding substance
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69607034T
Other languages
English (en)
Other versions
DE69607034D1 (de
Inventor
Suzanne Cox
Philip Lane
Emma Warbrick
Moore Glover
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of DE69607034D1 publication Critical patent/DE69607034D1/de
Application granted granted Critical
Publication of DE69607034T2 publication Critical patent/DE69607034T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69607034T 1995-05-11 1996-05-02 Pcna bindende substanz Expired - Fee Related DE69607034T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9509557.6A GB9509557D0 (en) 1995-05-11 1995-05-11 PCNA binding substance
PCT/GB1996/001056 WO1996035715A2 (en) 1995-05-11 1996-05-02 Pcna binding substance

Publications (2)

Publication Number Publication Date
DE69607034D1 DE69607034D1 (de) 2000-04-13
DE69607034T2 true DE69607034T2 (de) 2000-08-03

Family

ID=10774309

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69607034T Expired - Fee Related DE69607034T2 (de) 1995-05-11 1996-05-02 Pcna bindende substanz

Country Status (10)

Country Link
US (1) US6613878B1 (de)
EP (1) EP0871655B1 (de)
JP (1) JPH11504933A (de)
KR (1) KR19990008407A (de)
AT (1) ATE190318T1 (de)
AU (1) AU705096B2 (de)
CA (1) CA2218327A1 (de)
DE (1) DE69607034T2 (de)
GB (1) GB9509557D0 (de)
WO (1) WO1996035715A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935797A (en) * 1994-06-16 1999-08-10 Stanford University Interaction of MHC Class II proteins with members of the PCNA family of proteins
DE69736351D1 (de) 1996-05-08 2006-08-31 Cyclacel Ltd Methoden und mittel zur hemmung der cdk4-aktivität
AU6412098A (en) 1997-03-14 1998-10-12 University Court Of The University Of Glasgow, The Methods for identifying cell cycle regulators
US7166475B2 (en) * 1999-02-26 2007-01-23 Cyclacel Ltd. Compositions and methods for monitoring the modification state of a pair of polypeptides
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
US7449544B2 (en) 1999-11-30 2008-11-11 Cyclacel Limited p21 peptides
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
US7294471B2 (en) 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
US8653039B2 (en) 2006-02-17 2014-02-18 Robert J. Hickey Peptide based inhibition of caPCNA interaction in cancer
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
EP2538959A1 (de) * 2010-02-24 2013-01-02 Institut National de la Santé et de la Recherche Médicale Verbindungen zur behandlung von entzündung und neutropenie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
ES2201064T3 (es) 1992-10-16 2004-03-16 Cold Spring Harbor Laboratory Transposicion del complejo de ciclina y usos relacionados del mismo.
JP3822232B2 (ja) 1993-08-30 2006-09-13 ベイラー・カレッジ・オブ・メディシン 老化細胞由来ｄｎａ合成阻害因子
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof

Also Published As

Publication number Publication date
KR19990008407A (ko) 1999-01-25
ATE190318T1 (de) 2000-03-15
JPH11504933A (ja) 1999-05-11
DE69607034D1 (de) 2000-04-13
AU705096B2 (en) 1999-05-13
US6613878B1 (en) 2003-09-02
AU5508396A (en) 1996-11-29
EP0871655B1 (de) 2000-03-08
CA2218327A1 (en) 1996-11-14
GB9509557D0 (en) 1995-07-05
WO1996035715A2 (en) 1996-11-14
EP0871655A2 (de) 1998-10-21
WO1996035715A3 (en) 1996-12-27

Similar Documents

Publication Publication Date Title
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
DE69334266D1 (de) Therapeutische Zusammensetzungen aus Antikorper und Antisens Nukleinsäuren gegen Serrate
EA199900939A1 (ru) Остеопротегерин-связывающие белки и рецепторы
IL101728A0 (en) Human notch and delta,binding domains in toporhythmic proteins,and methods based thereon
ATE368053T1 (de) Antimikrobielle peptide
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
DE69607034T2 (de) Pcna bindende substanz
RU93045577A (ru) Слитные полипептиды
DE69516416T2 (de) Feststellung der wechselwirkungsstelle zwischen p21-waf und pcna und deren therapeutischen verwendungen
ATE290315T1 (de) Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits
DE3584775D1 (de) Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken.
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
BG103872A (en) Glycoconjugates of 20(s)-camptotecin
BR9510067A (pt) Peptídio capaz de interagir com o domínio sh3 da proteína gap anticorpo ou fragmento de anticorpo dirigido contra um polipeptídeo sequência nucleotídica codificando para um polipeptídio ácido nucléico anti-sentido capaz de inibir ao menos parcialmente a produção de polipeptídeos sua utilização composição farmacêutica e utilização de um anticorpo ou fragmento de anticorpo
DE69940927D1 (de) PEPTIDFRAGMENTE MIT DEN ZELLTOD VERHINDERNDEr AKTIVITÄT
NO922421D0 (no) Collagenbindende protein, samt fremstilling derav
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
DE59208025D1 (de) Neue thrombininhibitorische proteine aus landblutegeln
GB2357507A (en) Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants
WO2002021138A3 (de) Die m30-genfamilie und ihre verwendung
DE59914155D1 (de) Neue peptidfragmente zur reinigung von proteinen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee